中国医学创新2024，Vol.21Issue(33)：36-39,4.DOI:10.3969/j.issn.1674-4985.2024.33.009
利妥昔单抗治疗对特发性膜性肾病患者临床效果及安全性的影响
Effects of Rituximab on Clinical Efficacy and Safety of Patients with Idiopathic Membranous Nephropathy
摘要
Abstract
Objective:To analyze the clinical efficacy and safety of Rituximab in the treatment of idiopathic membranous nephropathy.Method:The clinical data of 62 patients with idiopathic membranous nephropathy admitted to Department of Nephrology,Shangrao People's Hospital from January 2022 to May 2023 were retrospectively analyzed.All patients were initially treated with Rituximab.24 h urinary protein quantity,serum creatinine(Scr),albumin(ALB),anti-phospholipase A2 receptor(PLA2R)antibody,and CD19+B cell count of patients were recorded before treatment and 1,3,6,and 12 months after treatment,and the clinical efficacy and safety were analyzed.Result:3,6 and 12 months after treatment,the 24 h urinary protein quantity of patients was decreased compared with that before treatment,and ALB was increased compared with that before treatment,1,3,6 and 12 months after treatment,the anti-PLA2R antibody and CD19+B cell count of patients were significantly decreased compared with those before treatment,the differences were statistically significant(P<0.05).12 months after treatment,35 of 62 patients with idiopathic membranous nephropathy had complete remission,accounting for 56.45%;there were 24 cases with partial remission,accounting for 38.71%;there were 3 cases without remission,accounting for 4.84%,and a total of 59 cases were effective,accounting for 95.16%.During the treatment period,only 2 of 62 patients with idiopathic membranous nephropathy had an infusion reaction,which improved after slowing down the infusion speed.Conclusion:Rituximab is safe and effective in the treatment of idiopathic membranous nephropathy.关键词
利妥昔单抗/特发性膜性肾病/肾功能Key words
Rituximab/Idiopathic membranous nephropathy/Renal function引用本文复制引用
徐倩,黄翠,万峻宏..利妥昔单抗治疗对特发性膜性肾病患者临床效果及安全性的影响[J].中国医学创新,2024,21(33):36-39,4.基金项目
江西省卫生健康委科技计划项目(202212745) （202212745）
